141 related articles for article (PubMed ID: 37741716)
21. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Lai GGY; Lim TH; Lim J; Liew PJR; Kwang XL; Nahar R; Aung ZW; Takano A; Lee YY; Lau DPX; Tan GS; Tan SH; Tan WL; Ang MK; Toh CK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Yuan J; Lim TKH; Lim AST; Hillmer AM; Lim WT; Iyer NG; Tam WL; Zhai W; Tan EH; Tan DSW
J Clin Oncol; 2019 Apr; 37(11):876-884. PubMed ID: 30676858
[TBL] [Abstract][Full Text] [Related]
22. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
[TBL] [Abstract][Full Text] [Related]
23. [Capmatinib in advanced NSCLC for previously treated patients with MET exon 14 skipping mutation].
Basse C; Régaldo-Saint Blancard L
Bull Cancer; 2023 Sep; 110(9):869-871. PubMed ID: 37442707
[No Abstract] [Full Text] [Related]
24. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring
Le X; Hong L; Hensel C; Chen R; Kemp H; Coleman N; Ciunci CA; Liu SV; Negrao MV; Yen J; Xia X; Scheuenpflug J; Stroh C; Juraeva D; Tsao A; Hong D; Raymond V; Paik P; Zhang J; Heymach JV
JCO Precis Oncol; 2021; 5():. PubMed ID: 34957368
[TBL] [Abstract][Full Text] [Related]
25. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations.
Uehara Y; Watanabe K; Hakozaki T; Yomota M; Hosomi Y
Thorac Cancer; 2022 Jun; 13(11):1703-1711. PubMed ID: 35491960
[TBL] [Abstract][Full Text] [Related]
27. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
28. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Rotow JK; Gui P; Wu W; Raymond VM; Lanman RB; Kaye FJ; Peled N; Fece de la Cruz F; Nadres B; Corcoran RB; Yeh I; Bastian BC; Starostik P; Newsom K; Olivas VR; Wolff AM; Fraser JS; Collisson EA; McCoach CE; Camidge DR; Pacheco J; Bazhenova L; Li T; Bivona TG; Blakely CM
Clin Cancer Res; 2020 Jan; 26(2):439-449. PubMed ID: 31548343
[TBL] [Abstract][Full Text] [Related]
29. Multicenter real-world data of patients harboring rare mutations other than EGFR or ALK in advanced or metastatic non-small cell lung cancer.
Lee SY; Kim YC; Lee KY; Lee SY; Lee SY; Lee MK; Lee JE; Jang SH; Jang TW; Choi CM
Thorac Cancer; 2022 Feb; 13(3):380-385. PubMed ID: 34881519
[TBL] [Abstract][Full Text] [Related]
30. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW
Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593
[TBL] [Abstract][Full Text] [Related]
31. Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study.
Liu L; Kalyani FS; Yang H; Zhou C; Xiong Y; Zhu S; Yang N; Qu J
Front Oncol; 2021; 11():649766. PubMed ID: 34249687
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
[TBL] [Abstract][Full Text] [Related]
33. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
[TBL] [Abstract][Full Text] [Related]
34. New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer.
Le X; Heymach JV
Oncologist; 2020 Oct; 25(10):822-825. PubMed ID: 33400286
[TBL] [Abstract][Full Text] [Related]
35. Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.
Lai GGY; Guo R; Drilon A; Shao Weng Tan D
Cancer Treat Rev; 2022 Nov; 110():102444. PubMed ID: 36108503
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of
Yu Y; Zhang Q; Zhang J; Lu S
J Cancer Res Ther; 2019; 15(4):909-913. PubMed ID: 31436251
[TBL] [Abstract][Full Text] [Related]
37. Amplification of Wild-type
Bahcall M; Awad MM; Sholl LM; Wilson FH; Xu M; Wang S; Palakurthi S; Choi J; Ivanova EV; Leonardi GC; Ulrich BC; Paweletz CP; Kirschmeier PT; Watanabe M; Baba H; Nishino M; Nagy RJ; Lanman RB; Capelletti M; Chambers ES; Redig AJ; VanderLaan PA; Costa DB; Imamura Y; Jänne PA
Clin Cancer Res; 2018 Dec; 24(23):5963-5976. PubMed ID: 30072474
[TBL] [Abstract][Full Text] [Related]
38. MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.
Wong SK; Alex D; Bosdet I; Hughesman C; Karsan A; Yip S; Ho C
Lung Cancer; 2021 Apr; 154():142-145. PubMed ID: 33667719
[TBL] [Abstract][Full Text] [Related]
39. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
Ludovini V; Bianconi F; Pistola L; Pistola V; Chiari R; Colella R; Bellezza G; Tofanetti FR; Siggillino A; Baldelli E; Flacco A; Giuffrida D; Sidoni A; Crinò L
Cancer Chemother Pharmacol; 2012 May; 69(5):1289-99. PubMed ID: 22302407
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
